ABCM

Abcam plc [ABCM] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ABCM Stock Summary

Earnings have grown 14.68% per last year.

Earnings are expected to rise 43.42% next year

An RSI reading of 70 or higher indicates an overbought or overvalued condition.

EPS has been decreasing for the past 3 years (Yearly statements)

ABCM has less than 1 year of cash runway

In the News

08:14 16 Apr 2024 ABCM

Danaher completes $5.7 billion acquisition of Abcam

Medical tools supplier Danaher said on Wednesday it has completed the $5.7 billion acquisition of Abcam , overcoming the initial opposition from the founder of the protein consumables maker.

08:46 16 Apr 2024 ABCM

Exlusive: Why Abcam founder believes Danaher's acquisition offer falls short

In an exclusive interview with Thomas Warner (TW) of Proactive London, Dr Jonathan Milner (JM), the founder of life sciences company Abcam PLC (NASDAQ:ABCM), discusses why he believes the $24 per share acquisition offer from Danaher (NYSE:DHR) severely undervalues the company. Milner criticises the timing of the deal and advises shareholders to consider whether the $5.7 billion acquisition is in their best interest.

12:47 16 Apr 2024 ABCM

GMED or ABCM: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Abcam PLC Sponsored ADR (ABCM). But which of these two stocks offers value investors a better bang for their buck right now?

04:55 16 Apr 2024 ABCM

Danaher Buys Abcam for $5.7 Billion to Expand Its Product Offerings

Medical tool supplier Danaher (DHR) is expanding its product offerings by purchasing British biotech firm Abcam Plc (ABCM) for $5.7 billion, including debt.

09:32 16 Apr 2024 ABCM

Danaher acquires biotech supplier Abcam for $5.7B

Danaher (NYSE:DHR) said it will be acquiring UK-based biotechnology supplier Abcam (AIM:ABC) for $24 per share or a total enterprise value of about $5.7 billion. Danaher (NYSE:DHR) beat out rivals who were also bidding for the company including Agilent Technologies (NYSE:A), according to media reports.

08:33 16 Apr 2024 ABCM

Medical tech firm Danaher to buy Abcam in deal valued at $5.7 bln

Danaher Corp said on Monday it would buy smaller rival Abcam Plc in a deal valued at $5.7 billion including debt, as the medical tools supplier eyes bigger contracts by expanding its services.

08:32 16 Apr 2024 ABCM

Danaher to Buy Abcam in $5.7 Billion Deal. Investors Don't Like the Premium.

The industrial scientific-supplies company agrees to acquire all shares outstanding for $24.00 each.

07:54 16 Apr 2024 ABCM

Abcam agrees to be acquired by Danaher in $5.7B deal

Abcam Plc stock ABCM, +3.87% was up 0.4% in premarket trades Monday after it said it agreed to be acquired by Danaher Corp. DHR, +0.78% for $24 a share in cash in a deal that values the maker of antibodies and reagents for drug discovery efforts at about $5.7 billion including debt. The price amounts to a premium of 64 cents a share, or 2.7% over its closing price of $23.36 on Friday.

02:04 16 Apr 2024 ABCM

Exclusive: Danaher in the lead to acquire biomedical equipment vendor Abcam-sources

Danaher Corp is in the lead to acquire Abcam Plc , a provider of supplies to life science researchers with a market value of $5.1 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday.

03:44 16 Apr 2024 ABCM

Why Shares of Abcam Are Jumping Friday

Abcam specializes in products, such as assays or reagents, used in biologic drug discovery. The company saw revenue grow but reported a loss in 2022.

ABCM Financial details

Company Rating

Market Cap

5.52B

Income

275K

Revenue

458.15M

Book val./share

3.09

Cash/share

0.34

Dividend

Dividend %

Employees

1.76K

Optionable

Shortable

Yes

Earnings

31 Aug 2023

P/E

15994.26

Forward P/E

PEG

P/S

9.47

P/B

6.12

P/C

70.56

P/FCF

100.6

Quick Ratio

0.99

Current Ratio

1.35

Debt / Equity

0.3

LT Debt / Equity

0.12

EPS (TTM)

EPS next Y

EPS next Q

1.34

EPS this Y

-295.79%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

6.83%

Revenue Q/Q

EPS Q/Q

SMA20

3.27%

SMA50

SMA100

Inst Own

56.2%

Inst Trans

0.67%

ROA

ROE

ROC

0.06%

Gross Margin

78%

Oper. Margin

10%

Profit Margin

Payout

2273%

Shs Outstand

230.15M

Shs Float

192.43M

Target Price

52W Range

12.48-25.32

52W High

-4.04%

52W Low

+99.92%

RSI

75.17

Rel Volume

Avg Volume

5.82M

Volume

Perf Week

Perf Month

3.72%

Perf Quarter

Perf Half Y

4.49%

Beta

0.863

Volatility

0%, 0.38%

Prev Close

Price

23.99

Change

ABCM Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2019-06-30	2020-06-30	2021-06-30	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.26	1.24	1.42	1.38	1.58
Net income per share	0.22	0.06	0.07	0.02	-0.04
Operating cash flow per share	0.34	0.3	0.34	0.27	0.13
Free cash flow per share	0.14	0.13	0.07	0.01	-0.06
Cash per share	0.42	0.89	0	0.42	0.39
Book value per share	1.86	2.4	0	2.87	3.18
Tangible book value per share	0.76	0.74	0	0.25	0.44
Share holders equity per share	1.86	2.4	0	2.87	3.18
Interest debt per share	0	1.13	0	1.01	1
Market cap	3B	2.77B	2.9B	3.99B	2.95B
Enterprise value	2.92B	2.82B	0	4.13B	3.09B
P/E ratio	66.75	221.93	198.6	907.62	-347.25
Price to sales ratio	11.56	10.67	9.74	12.66	8.16
POCF ratio	42.79	44.03	40.33	63.49	102.84
PFCF ratio	100.8	101.62	197.25	1.29K	-234.26
P/B Ratio	7.81	5.52	0	6.09	4.06
PTB ratio	7.81	5.52	0	6.09	4.06
EV to sales	11.22	10.85	0	13.09	8.53
Enterprise value over EBITDA	31.36	42.49	0	87.09	72.28
EV to operating cash flow	41.55	44.78	0	65.63	107.54
EV to free cash flow	97.87	103.33	0	1.33K	-244.96
Earnings yield	0.01	0	0.01	0	0
Free cash flow yield	0.01	0.01	0.01	0	0
Debt to equity	0	0.47	0	0.35	0.31
Debt to assets	0	0.29	0	0.23	0.21
Net debt to EBITDA	-0.94	0.71	0	2.84	3.16
Current ratio	3.79	1.75	0	1.13	1.27
Interest coverage	187	3.75	8.06	4.18	-1.89
Income quality	1.25	6	2.55	8.86	-2.84
Dividend Yield	0.01	0.01	0.01	0.01	0.01
Payout ratio	0.55	2	1.71	5.68	-2.94
Sales general and administrative to revenue	0.34	0.46	0.4	0	0
Research and developement to revenue	0.04	0.07	0.06	0.09	0.16
Intangibles to total assets	0.51	0.43	0	0.61	0.59
Capex to operating cash flow	-0.58	-0.57	-0.8	-0.95	-1.44
Capex to revenue	-0.16	-0.14	-0.19	-0.19	-0.11
Capex to depreciation	-2.62	-1.19	-1.62	-1.46	-0.78
Stock based compensation to revenue	0.03	0.04	0.05	0.06	0.06
Graham number	3.02	1.79	0	1.11	1.63
ROIC	0.12	0.02	0	0.01	-0.01
Return on tangible assets	0.21	0.03	0	0.01	-0.02
Graham Net	0.38	-0.3	0	-0.79	-0.61
Working capital	126.5M	119.2M	0	24.3M	53.6M
Tangible asset value	157.2M	155.4M	0	57.1M	100.7M
Net current asset value	109.9M	-30M	0	-118.5M	-74.3M
Invested capital	0	0.47	0	0.35	0.31
Average receivables	43.9M	49.65M	0	0	61.75M
Average payables	43.8M	42.8M	0	0	14.35M
Average inventory	32.8M	38.35M	0	0	63.1M
Days sales outstanding	68.11	71.32	0	38.42	91.12
Days payables outstanding	198.92	200.34	0	51.86	63.23
Days of inventory on hand	171.32	186.16	0	233.95	272.15
Receivables turnover	5.36	5.12	0	9.5	4.01
Payables turnover	1.83	1.82	0	7.04	5.77
Inventory turnover	2.13	1.96	0	1.56	1.34
ROE	0.12	0.02	0	0.01	-0.01
Capex per share	-0.2	-0.17	-0.27	-0.26	-0.18

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-10	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.4	0.39	0.73	0.44	0.44
Net income per share	0.01	-0.03	-0.04	0.04	0.04
Operating cash flow per share	0.06	0	0	0.06	0.06
Free cash flow per share	0.05	-0.03	-0.03	0.04	0.04
Cash per share	0.48	0.39	0.39	0.34	0.34
Book value per share	3.16	3.18	3.18	3.09	3.09
Tangible book value per share	0.44	0.44	0.44	0.52	0.52
Share holders equity per share	3.16	3.18	3.18	3.09	3.09
Interest debt per share	1	0.01	0.97	0.01	0.94
Market cap	2.76B	3.07B	2.95B	3.22B	4.51B
Enterprise value	2.88B	2.98B	3.09B	3.14B	4.65B
P/E ratio	237.53	-107.36	-78.7	95.71	134.34
Price to sales ratio	29.76	34.79	17.7	31.65	44.43
POCF ratio	184.92	-5.58K	-5.37K	235.6	330.69
PFCF ratio	217.82	-458.3	-440.46	365.44	512.95
P/B Ratio	3.79	4.22	4.06	4.47	6.28
PTB ratio	3.79	4.22	4.06	4.47	6.28
EV to sales	31.05	33.79	18.51	30.88	45.79
Enterprise value over EBITDA	149	125.54	-103.38	107.24	159.04
EV to operating cash flow	193	-5.42K	-5.61K	229.81	340.8
EV to free cash flow	227.33	-445.02	-460.6	356.47	528.63
Earnings yield	0	0	0	0	0
Free cash flow yield	0	0	0	0	0
Debt to equity	0.32	0	0.31	0	0.3
Debt to assets	0.22	0	0.21	0	0.21
Net debt to EBITDA	6.23	-3.75	-4.52	-2.7	4.72
Current ratio	1.26	1.27	1.27	1.35	1.35
Interest coverage	9.47	9.94	6.6	8.27	8.27
Income quality	5.14	0.08	0.08	1.63	1.63
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	-0.67	0	0
Sales general and administrative to revenue	0	0	0.59	0	0
Research and developement to revenue	0.1	0.21	-0.17	0.1	0.1
Intangibles to total assets	0.59	0.59	0.59	0.58	0.58
Capex to operating cash flow	-0.15	11.18	11.18	-0.36	-0.36
Capex to revenue	-0.02	-0.07	-0.04	-0.05	-0.05
Capex to depreciation	-0.18	-0.67	-0.67	-0.38	-0.38
Stock based compensation to revenue	0.07	0.07	0.04	0.04	0.04
Graham number	0.94	1.49	1.71	1.58	1.58
ROIC	0.01	0.03	-0.01	0.02	0.01
Return on tangible assets	0.01	-0.02	-0.02	0.02	0.02
Graham Net	-0.63	-0.68	-0.61	-0.54	-0.49
Working capital	54M	53.6M	53.6M	66.9M	66.9M
Tangible asset value	101.7M	100.7M	100.7M	120.2M	120.2M
Net current asset value	-79.3M	-74.3M	-74.3M	-52.1M	-52.1M
Invested capital	0.32	0	0.31	0	0.3
Average receivables	36.05M	69.55M	78.65M	91.3M	100.45M
Average payables	56.7M	36.25M	15.8M	38.6M	61.4M
Average inventory	57.5M	62.75M	68M	67.15M	66.3M
Days sales outstanding	70.08	68.33	48.75	81.76	96.2
Days payables outstanding	225.8	65.68	45.36	228.82	228.82
Days of inventory on hand	228.98	282.68	195.22	247.08	247.08
Receivables turnover	1.28	1.32	1.85	1.1	0.94
Payables turnover	0.4	1.37	1.98	0.39	0.39
Inventory turnover	0.39	0.32	0.46	0.36	0.36
ROE	0	-0.01	-0.01	0.01	0.01
Capex per share	-0.01	-0.03	-0.03	-0.02	-0.02

ABCM Frequently Asked Questions

What is Abcam plc stock symbol ?

Abcam plc is a GB stock and trading under the symbol ABCM

What is Abcam plc stock quote today ?

Abcam plc stock price is $23.99 today.

Is Abcam plc stock public?

Yes, Abcam plc is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 5.82M
Market Capitalization 5.52B
Employee 1.76K
CEO Mr. Alan Thomas Hirzel BS, M.B.A., M.S.
Headquarters Cambridge,GB
IPO Date 2020-10-22
Website https://www.abcam.com

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.